Literature DB >> 11712865

Protein kinase C isoforms as therapeutic targets in nervous system disease states.

F Battaini1.   

Abstract

Neuronal tissues display high levels of protein kinase C (PKC) activity and isoform expression. The activation of this enzymatic system is important in the control of short and long term brain functions (ion channel regulation, receptor modulation, neurotransmitter release, synaptic potentiation/depression, neuronal survival) that are related to diverse brain pathologies. This review will describe recent developments in PKC regulation and changes in levels, isoforms and activation in acute and chronic neurodegenerative pathologies as well as in affective and psychic disorders. The recent availability of isoform selective inhibitors and activators may help to understand better the relevance of PKC in central nervous system (CNS) physiology and pathology and to identify new and safer pharmacologic strategies to be tested in different disease states. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712865     DOI: 10.1006/phrs.2001.0893

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  24 in total

1.  Protein kinase C-mediated phosphorylation of the μ-opioid receptor and its effects on receptor signaling.

Authors:  Bo Feng; Zhihua Li; Jia Bei Wang
Journal:  Mol Pharmacol       Date:  2011-01-06       Impact factor: 4.436

2.  Involvement of protein kinase C-epsilon in activity-dependent potentiation of large dense-core vesicle exocytosis in chromaffin cells.

Authors:  Yong-Soo Park; Eun-Mi Hur; Bo-Hwa Choi; Eunyee Kwak; Dong-Jae Jun; Su-Jin Park; Kyong-Tai Kim
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

3.  Disruption of astrocytic glutamine turnover by manganese is mediated by the protein kinase C pathway.

Authors:  Marta Sidoryk-Wegrzynowicz; Eunsook Lee; Ni Mingwei; Michael Aschner
Journal:  Glia       Date:  2011-08-02       Impact factor: 7.452

Review 4.  Oxidative and inflammatory pathways in Parkinson's disease.

Authors:  Rebecca L Miller; Marilyn James-Kracke; Grace Y Sun; Albert Y Sun
Journal:  Neurochem Res       Date:  2008-03-25       Impact factor: 3.996

5.  Synthesis and Biological Evaluation of Several Bryostatin Analogues Bearing a Diacylglycerol Lactone C-Ring.

Authors:  David O Baumann; Kevin M McGowan; Noemi Kedei; Megan L Peach; Peter M Blumberg; Gary E Keck
Journal:  J Org Chem       Date:  2016-08-23       Impact factor: 4.354

6.  Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Authors:  Colleen Carpenter; Roderick J Sorenson; Yafei Jin; Szymon Klossowski; Tomasz Cierpicki; Margaret Gnegy; Hollis D Showalter
Journal:  Bioorg Med Chem       Date:  2016-09-04       Impact factor: 3.641

7.  DOR activation inhibits anoxic/ischemic Na+ influx through Na+ channels via PKC mechanisms in the cortex.

Authors:  Dongman Chao; Xiaozhou He; Yilin Yang; Alia Bazzy-Asaad; Lawrence H Lazarus; Gianfranco Balboni; Dong H Kim; Ying Xia
Journal:  Exp Neurol       Date:  2012-05-15       Impact factor: 5.330

8.  Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C.

Authors:  Jian Qiu; Martha A Bosch; Sandra C Tobias; David K Grandy; Thomas S Scanlan; Oline K Ronnekleiv; Martin J Kelly
Journal:  J Neurosci       Date:  2003-10-22       Impact factor: 6.167

9.  Rottlerin protected dopaminergic cell line from cytotoxicity of 6-hydroxydopamine by inhibiting PKCdelta phosphorylation.

Authors:  Ying Fan; Yan-Qiao Zhang; Dian-Jun Sun; Yi-Na Zhang; Xiao-Wei Wu; Jing Li
Journal:  Neurosci Bull       Date:  2009-08       Impact factor: 5.203

10.  Protein kinase C activity is associated with prefrontal cortical decline in aging.

Authors:  Avis R Brennan; Peixiong Yuan; Dara L Dickstein; Anne B Rocher; Patrick R Hof; Husseini Manji; Amy F T Arnsten
Journal:  Neurobiol Aging       Date:  2007-10-04       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.